세계의 암 면역요법 시장 : 치료법의 경쟁 - 치료법별, 암별, 고객별 면역암 치료 시장 예측 : 주요 컨설턴트 가이드 첨부(2025-2029년)

Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2025 to 2029

US $ 6,995 ￦ 10,121,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 15,185,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 20,249,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

암치료에 있어서의 혁명이 진행중입니다. 신체의 자연 면역 방어를 이용한 새로운 치료법이, 과거 없는 성공을 거두고 있습니다. 극적인 성장을 이루려고 합니다.

본 보고서는 세계의 암 면역요법 시장에 대해 조사했으며, 시장 개요와 함께 치료법별, 암별, 고객별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 시장 가이드

제2장 소개와 시장 정의

• 암 면역요법이란 무엇인가
• 면역요법- 다가오는 치료법
• 시장의 정의
• 조사 방법
• 미국의 의료 시장과 의약품 지출- 전망

제3장 면역요법- 면역기술 가이드

• 면역 시스템
• 면역종양학 기술

제4장 업계 개요

• 시장 진출기업 - 역할과 영향

제5장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 치료 기술 개발

제6장 암 면역요법의 최근 동향

제7장 주요 기업 프로파일

• AbbVie
• Achilles Therapeutics
• Acumen Pharmaceuticals
• Adagene
• Adaptimmune Therapeutics
• Adicet Bio
• ALX Oncology Holdings
• Ambrx Biopharma
• Amgen
• Apexigen
• Arcus Biosciences
• argenx
• AstraZeneca
• Atreca
• Avalo Therapeutics
• Avid Bioservices
• Bavarian Nordic
• BioAtla
• Biogen Inc.
• BioNTech
• Bolt Biotherapeutics
• Bristol-Myers Squibb
• Candel Therapeutics
• Caribou Biosciences
• Celldex Therapeutics
• Checkpoint Therapeutics
• Chinook Therapeutics
• Corvus Pharmaceuticals
• Cullinan Oncology
• Eli Lilly
• EOM Pharmaceuticals
• Evaxion Biotech
• Genenta Science
• Gilead Sciences
• Gracell Biotechnologies
• Greenwich LifeSciences
• Gritstone bio
• Harpoon Therapeutics
• ImmunityBio
• Immunocore Holdings
• Immunome
• IMV Inc
• Incyte
• Indaptus Therapeutics
• Instil Bio
• Iovance Biotherapeutics
• Johnson & Johnson
• Marker Therapeutics
• Medicenna Therapeutics
• Merck & Co.
• Merus
• Moderna
• Mustang Bio
• Nanobiotix
• Neoleukin Therapeutics
• Novartis
• Novavax
• Oncorus
• PDS Biotechnology
• Pfizer
• Regeneron Pharmaceuticals
• Roche
• Sanofi
• Sensei Biotherapeutics
• Senti Biosciences
• Surface Oncology
• Takeda Pharmaceutical
• TC Biopharm
• ThermoGenesis Holdings
• UroGen Pharma
• Werewolf Therapeutics
• Xilio Therapeutics
• Zymeworks

제8장 세계의 암 면역요법 시장

• 세계 시장 개요, 국가별
• 세계 시장 개요, 치료별
• 세계 시장 개요, 암별
• 세계 시장 개요, 고객별

제9장 세계의 암 면역요법 시장-치료별

• MAB
• 사이토카인
• 백신
• 셀 베이스
• 억제제/작용제
• 기타

제10장 세계의 암 면역요법 시장-암별

• 유방암
• 대장암
• 경부암
• 폐암
• 전암 상태
• 전립선암
• 흑색종
• 혈액암
• 기타

제11장 세계의 암 면역요법 시장-고객별

• 제약회사
• 클리닉
• 기타

제12장 부록

JHS

영문 목차

영문목차

Report Overview:

Are cures for cancer in sight? What is the opportunity in this market? What companies are poised to benefit? Is disruption a possibility? Find out in this comprehensive report.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR - T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon.

Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

• 2.1. What is Cancer Immunotherapy?
• 2.2. Immunotherapy - the looming cures
• 2.3. Market Definition
  • 2.3.1. Market Size
  • 2.3.2. Currency
  • 2.3.3. Years
• 2.4. Methodology
  • 2.4.1. Methodology
  • 2.4.2. Sources
  • 2.4.3. Authors
• 2.5. U.S. Medical Market and Pharmceutical Spending - Perspective
  • 2.5.1. Global Expenditures for Medicines

3. Immunotherapy - Guide to Immune Technologies

• 3.1. The Immune System
  • 3.1.1. Innate immune system
    • 3.1.1.1. Surface barriers
    • 3.1.1.2. Inflammation
    • 3.1.1.3. Complement system
    • 3.1.1.4. Cellular barriers
    • 3.1.1.5. Natural killer cells
  • 3.1.2. Adaptive immune system
    • 3.1.2.1. Lymphocytes
    • 3.1.2.2. Killer T cells
    • 3.1.2.3. Helper T cells
    • 3.1.2.4. Gamma delta T cells
    • 3.1.2.5. B lymphocytes and antibodies
  • 3.1.3. Tumor immunology - the immune surveillance system
• 3.2. Immuno Oncology Technologies
  • 3.2.1. Monoclonal Antibodies
    • 3.2.1.1. Outlook for Monoclonal Antibodies
    • 3.2.1.2. Companies with Monoclonal Antibodies in their Pipeline
  • 3.2.2. Cancer vaccines
    • 3.2.2.1. Outlook for Cancer Vaccines
    • 3.2.2.2. Companies with Cancer Vaccines in their Pipeline
  • 3.2.3. Cytokines
    • 3.2.3.1. Outlook for Cytokines
    • 3.2.3.2. Companies with Cytokines in their Pipeline
  • 3.2.4. Cell Based Therapies
    • 3.2.4.1. Outlook for Cell Based Therapies
    • 3.2.4.2. Companies with Cell Based Therapies in their Pipeline
  • 3.2.5. Inhibitors/Agonists
    • 3.2.5.1. Outlook for Inhibitors/Agonists
    • 3.2.5.2. Companies with Inhibitors/Agonists in their Pipeline
  • 3.2.6. Antibody Drug Conjugates
    • 3.2.6.1. Outlook for Antibody Drug Conjugates
    • 3.2.6.2. Companies with Antibody Drug Conjugates in their Pipeline
  • 3.2.7. Others
    • 3.2.7.1. Outlook for Other Therapeutics
    • 3.2.7.2. Companies with Viral Therapeutics in their Pipeline
    • 3.2.7.3. Companies with Other Therapeutics in their Pipeline

4. Industry Overview

• 4.1. Market Players - Roles & Impacts
  • 4.1.1. Drug manufacturers - Larger/pharmaceutical
  • 4.1.2. Drug manufacturers - Generic
  • 4.1.3. Contract Research and Manufacturing
  • 4.1.4. In Vitro Diagnostics Industry
  • 4.1.5. Drug Marketing Companies
  • 4.1.6. Biotechnology Companies
  • 4.1.7. Regulatory Bodies

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Outcome potential
  • 5.1.2. Fast tracking
  • 5.1.3. Funding
  • 5.1.4. Technology Environment
  • 5.1.5. Target Solutions
• 5.2. Factors Limiting Growth
  • 5.2.1. Cost of Treatment
  • 5.2.2. Clinical Trials Role
  • 5.2.3. Combinations
  • 5.2.4. Protocols
• 5.3. Therapeutic Technology Development
  • 5.3.1. Combinations - Issues and Complexity
  • 5.3.2. Preference for a drug
  • 5.3.3. Problems of Immunity Engineering
  • 5.3.4. The Role of Cost
  • 5.3.5. The Disruption Dynamic
  • 5.3.6. CAR-T Cell Therapy
  • 5.3.7. The Next Five Years

6. Cancer Immunotherapy Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Merck, buys into new kind of cancer immunotherapy
• 6.3. Immunotherapy after surgery
• 6.4. Anti-CTLA-4 nanobody a promising approach
• 6.5. Continued Success with Immunotherapy in Melanoma
• 6.6. AC Immune Receives FDA Fast Track Designation
• 6.7. LTZ Announces Financing
• 6.8. Immunotherapy for Cancer Overview
• 6.9. Implantable device shrinks pancreatic tumors
• 6.10. mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence
• 6.11. Towards a Universal Cancer Immunotherapy
• 6.12. New Strategy May Improve T-Cell Therapy in Solid Tumors
• 6.13. Immunotherapy linked to increase in Medicare spending
• 6.14. Immunotherapy Effective with Ovarian Cancer
• 6.15. Cancer Immunotherapy Granted Fast Track

7. Profiles of Key Immunotherapy Companies

• 7.1. AbbVie
• 7.2. Achilles Therapeutics
• 7.3. Acumen Pharmaceuticals
• 7.4. Adagene
• 7.5. Adaptimmune Therapeutics
• 7.6. Adicet Bio
• 7.7. ALX Oncology Holdings
• 7.8. Ambrx Biopharma
• 7.9. Amgen
• 7.10. Apexigen
• 7.11. Arcus Biosciences
• 7.12. argenx
• 7.13. AstraZeneca
• 7.14. Atreca
• 7.15. Avalo Therapeutics
• 7.16. Avid Bioservices
• 7.17. Bavarian Nordic
• 7.18. BioAtla
• 7.19. Biogen Inc.
• 7.20. BioNTech
• 7.21. Bolt Biotherapeutics
• 7.22. Bristol-Myers Squibb
• 7.23. Candel Therapeutics
• 7.24. Caribou Biosciences
• 7.25. Celldex Therapeutics
• 7.26. Checkpoint Therapeutics
• 7.27. Chinook Therapeutics
• 7.28. Corvus Pharmaceuticals
• 7.29. Cullinan Oncology
• 7.30. Eli Lilly
• 7.31. EOM Pharmaceuticals
• 7.32. Evaxion Biotech
• 7.33. Genenta Science
• 7.34. Gilead Sciences
• 7.35. Gracell Biotechnologies
• 7.36. Greenwich LifeSciences
• 7.37. Gritstone bio
• 7.38. Harpoon Therapeutics
• 7.39. ImmunityBio
• 7.40. Immunocore Holdings
• 7.41. Immunome
• 7.42. IMV Inc
• 7.43. Incyte
• 7.44. Indaptus Therapeutics
• 7.45. Instil Bio
• 7.46. Iovance Biotherapeutics
• 7.47. Johnson & Johnson
• 7.48. Marker Therapeutics
• 7.49. Medicenna Therapeutics
• 7.50. Merck & Co.
• 7.51. Merus
• 7.52. Moderna
• 7.53. Mustang Bio
• 7.54. Nanobiotix
• 7.55. Neoleukin Therapeutics
• 7.56. Novartis
• 7.57. Novavax
• 7.58. Oncorus
• 7.59. PDS Biotechnology
• 7.60. Pfizer
• 7.61. Regeneron Pharmaceuticals
• 7.62. Roche
• 7.63. Sanofi
• 7.64. Sensei Biotherapeutics
• 7.65. Senti Biosciences
• 7.66. Surface Oncology
• 7.67. Takeda Pharmaceutical
• 7.68. TC Biopharm
• 7.69. ThermoGenesis Holdings
• 7.70. UroGen Pharma
• 7.71. Werewolf Therapeutics
• 7.72. Xilio Therapeutics
• 7.73. Zymeworks

8. The Global Market for Immuno-Oncology Therapeutics

• 8.1. Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Market by Therapy - Overview
  • 8.2.1. Table - Global Market by Therapy
  • 8.2.2. Chart - Global Market by Therapy - Base/Final Year Comparison
  • 8.2.3. Chart - Global Market by Therapy - Base Year
  • 8.2.4. Chart - Global Market by Therapy - End Year
  • 8.2.5. Chart - Global Market by Therapy - Share by Year
  • 8.2.6. Chart - Global Market by Therapy - Segments Growth
• 8.3. Global Market by Cancer - Overview
  • 8.3.1. Table - Global Market by Cancer
  • 8.3.2. Chart - Global Market by Cancer - Base/Final Year Comparison
  • 8.3.3. Chart - Global Market by Cancer - Base Year
  • 8.3.4. Chart - Global Market by Cancer - End Year
  • 8.3.5. Chart - Global Market by Cancer - Share by Year
  • 8.3.6. Chart - Global Market by Cancer - Segments Growth
• 8.4. Global Market by Customer - Overview
  • 8.4.1. Table - Global Market by Customer
  • 8.4.2. Chart - Global Market by Customer - Base/Final Year Comparison
  • 8.4.3. Chart - Global Market by Customer - Base Year
  • 8.4.4. Chart - Global Market by Customer - End Year
  • 8.4.5. Chart - Global Market by Customer - Share by Year
  • 8.4.6. Chart - Global Market by Customer - Segments Growth

9. Global Immuno-Oncology Therapy Markets - By Therapy

• 9.1. MAB
  • 9.1.1. Table MAB - by Country
  • 9.1.2. Chart - MAB Growth
• 9.2. Cytokine
  • 9.2.1. Table Cytokine - by Country
  • 9.2.2. Chart - Cytokine Growth
• 9.3. Vaccine
  • 9.3.1. Table Vaccine - by Country
  • 9.3.2. Chart - Vaccine Growth
• 9.4. Cell Based
  • 9.4.1. Table Cell Based - by Country
  • 9.4.2. Chart - Cell Based Growth
• 9.5. Inhibitor/Agonist
  • 9.5.1. Table Inhibitor/Agonist - by Country
  • 9.5.2. Chart - Inhibitor/Agonist Growth
• 9.6. Other IO Therapy
  • 9.6.1. Table Other IO Therapy - by Country
  • 9.6.2. Chart - Other IO Therapy Growth

10. Global Immuno-Oncology Therapeutic Markets - By Cancer

• 10.1. Breast
  • 10.1.1. Table Breast - by Country
  • 10.1.2. Chart - Breast Growth
• 10.2. ColoRectal
  • 10.2.1. Table ColoRectal - by Country
  • 10.2.2. Chart - ColoRectal Growth
• 10.3. Cervical
  • 10.3.1. Table Cervical - by Country
  • 10.3.2. Chart - Cervical Growth
• 10.4. Lung
  • 10.4.1. Table Lung - by Country
  • 10.4.2. Chart - Lung Growth
• 10.5. Precancer
  • 10.5.1. Table Precancer - by Country
  • 10.5.2. Chart - Precancer Growth
• 10.6. Prostate
  • 10.6.1. Table Prostate - by Country
  • 10.6.2. Chart - Prostate Growth
• 10.7. Melanoma
  • 10.7.1. Table Melanoma - by Country
  • 10.7.2. Chart - Melanoma Growth
• 10.8. Blood
  • 10.8.1. Table Blood - by Country
  • 10.8.2. Chart - Blood Growth
• 10.9. Other Cancer
  • 10.9.1. Table Other Cancer - by Country
  • 10.9.2. Chart - Other Cancer Growth

11. Global Immuno-Oncology Therapeutic Markets - By Customer

• 11.1. Pharma
  • 11.1.1. Table Pharma - by Country
  • 11.1.2. Chart - Pharma Growth
• 11.2. Clinic
  • 11.2.1. Table Clinic - by Country
  • 11.2.2. Chart - Clinic Growth
• 11.3. Other Customer
  • 11.3.1. Table Other Customer - by Country
  • 11.3.2. Chart - Other Customer Growth

12. Appendices

• 12.1. FDA Cancer Drug Approvals by Year
• 12.2. Clinical Trials Started
• 12.3. Prevalence of Cancer Treatments

관련자료